More sugars, more potency: diosgenin saponins hit RAS–ERK in head and neck cancer
- Diosgenin and two glycosylated derivatives were compared in head and neck squamous cell carcinoma cells and a subcutaneous xenograft model; activity rose steadily with the number of sugar groups.
- Network pharmacology plus machine learning narrowed the candidate genes, and docking suggested the saponins bind EPHB4 and ADAM17.
- A RAF1-RBD pull-down showed reduced active RAS and lower ERK phosphorylation, placing the effect upstream of ERK.
💡 Points Based on the abstract
A clean glycosylation SAR in vivo is the useful part. The target story is the weak part: network pharmacology, docking and a pull-down don't show that EPHB4 or ADAM17 engagement is what lowers RAS-GTP, and saponins are notorious membrane-active, promiscuous compounds. I'd run a membrane-disruption control and a genetic knockdown of those two proteins before taking the mechanism seriously.
Glycosylated steroidal saponins suppress HNSCC progression by targeting the RAS–ERK pathway ↗